近日,《英国癌症杂志》发布一篇题为“Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents”的研究论文,文中数据表明,zurletrectinib(ICP-723)与其他下一代药物相比,具有更强的体内脑渗透性和颅内活性。